Yosuke Minami

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 21

Top Topics

Peritoneal Dialysis

Chronic Kidney Disease

Top Venues

International journal of hematology

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Yosuke Minami, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Meryem Ktiouet Dawson, Itaru Matsumura
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International journal of hematology (2024)
Ryo Yoshimaru, Yosuke Minami
Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML. International journal of hematology (2024)
Yosuke Minami, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Meryem Ktiouet Dawson, Itaru Matsumura
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International journal of hematology 120 (3) (2024)
Hironori Arai, Hirotaka Matsui, Sung-Gi Chi, Yoshikazu Utsu, Shinichi Masuda, Nobuyuki Aotsuka, Yosuke Minami
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. International journal of molecular sciences 25 (1) (2024)
Hironori Arai, Hirotaka Matsui, Sung-Gi Chi, Yoshikazu Utsu, Shinichi Masuda, Nobuyuki Aotsuka, Yosuke Minami
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. International journal of molecular sciences 25 (1) (2024)
Hironori Arai, Hirotaka Matsui, Sung-Gi Chi, Yoshikazu Utsu, Shinichi Masuda, Nobuyuki Aotsuka, Yosuke Minami
Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. International journal of molecular sciences 25 (1) (2024)
Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, Yoji Ogasawara, Takaaki Ono, Masaya Okada, Tetsuzo Tauchi, Toshihiro Miyamoto, Kazunori Ohnishi, Emiko Sakaida, Shin Fujisawa, Yukio Kobayashi, Norio Asou, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki
Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. Blood advances (2024)
Takafumi Tsushima, Nobue Sato, Yong-Mei Guo, Hirotaka Nakamura, Kodai Kunisada, Song-Gi Chi, Kenta Akie, Yuki Takahashi, Saki Nakamura, Kaoru Shimada, Genichiro Ishii, Yosuke Minami, Junichiro Yuda
Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment. EJHaem 5 (3) (2024)
Yosuke Minami, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Meryem Ktiouet Dawson, Itaru Matsumura
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International journal of hematology 120 (3) (2024)
Takafumi Tsushima, Nobue Sato, Yong-Mei Guo, Hirotaka Nakamura, Kodai Kunisada, Song-Gi Chi, Kenta Akie, Yuki Takahashi, Saki Nakamura, Kaoru Shimada, Genichiro Ishii, Yosuke Minami, Junichiro Yuda
Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment. EJHaem 5 (3) (2024)
Yosuke Minami, Noriko Doki, Hiroshi Matsuoka, Takafumi Yokota, Akihiro Tomita, Naoto Takahashi, Kohmei Kubo, Tatsunori Goto, Keita Kirito, Akio Maki, Makoto Aoki, Meryem Ktiouet Dawson, Itaru Matsumura
Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. International journal of hematology 120 (3) (2024)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Delphine Rea, Carla Boquimpani, Michael J Mauro, Yosuke Minami, Alex Allepuz, Vikalp Kumar Maheshwari, Denise D'Alessio, Ying Wu, Rachael Lawrance, Sarunas Narbutas, Giora Sharf, Andreas Hochhaus
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Ryo Yoshimaru, Yosuke Minami
Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance. International journal of molecular sciences 24 (18) (2023)
Naoko Hosono, Sung-Gi Chi, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Motoki Eguchi, Takanobu Morishita, Reiki Ogasawara, Takeshi Kondo, Masamitsu Yanada, Kazuhito Yamamoto, Tsutomu Kobayashi, Junya Kuroda, Kensuke Usuki, Yoshikazu Utsu, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Naoto Takahashi, Satoshi Iyama, Kensuke Kojima, Yukinori Nakamura, Suguru Fukuhara, Koji Izutsu, Hikaru Abutani, Nobuhiko Yamauchi, Junichiro Yuda, Yosuke Minami, null null
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer science (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia (2023)
Naoko Hosono, Sung-Gi Chi, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Motoki Eguchi, Takanobu Morishita, Reiki Ogasawara, Takeshi Kondo, Masamitsu Yanada, Kazuhito Yamamoto, Tsutomu Kobayashi, Junya Kuroda, Kensuke Usuki, Yoshikazu Utsu, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Naoto Takahashi, Satoshi Iyama, Kensuke Kojima, Yukinori Nakamura, Suguru Fukuhara, Koji Izutsu, Hikaru Abutani, Nobuhiko Yamauchi, Junichiro Yuda, Yosuke Minami, null null
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer science (2023)
Suguru Fukuhara, Yuji Oshikawa-Kumade, Yasunori Kogure, Sumito Shingaki, Hirokazu Kariyazono, Yoshiya Kikukawa, Junji Koya, Yuki Saito, Mariko Tabata, Kota Yoshifuji, Kota Mizuno, Akiko Miyagi Maeshima, Hiromichi Matsushita, Masanaka Sugiyama, Chitose Ogawa, Yoshihiro Inamoto, Takahiro Fukuda, Masato Sugano, Nobuhiko Yamauchi, Yosuke Minami, Makoto Hirata, Teruhiko Yoshida, Takashi Kohno, Shinji Kohsaka, Hiroyuki Mano, Yuichi Shiraishi, Seishi Ogawa, Koji Izutsu, Keisuke Kataoka
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer science 113 (8) (2022)